Rally funds research in the following areas: -Under-studied cancer types -Innovative approaches to childhood cancer research which could lead to advanced studies or clinical trials -Studies that are likely to lead to a clinical trial, personalized, alternative, or integrated research proposals -Quality of life and survivorship research proposals

The Aniara Research Panel awards one yearly grant for specialized in hematology and coagulation research. All proposed projects must be in the coagulation/hematology scientific field. This year, the sponsor is asking for projects that deal specifically with EDS - Ehlers-Danlos syndrome - and its effects on hemostasis and thrombosis. Extensive bruising, spontaneous arterial rupture, rupture of hollow organs, and severe internal bleeding are predominant features in EDS. Patients suffering from such syndromes typically undergo hematological studies including evaluation of clotting factors, platelet aggregation, and bleeding time.

The Data Incubator is a Cornell-funded data science training organization. We run an advanced 8-week fellowship for PhDs looking to enter industry. A variety of innovative companies partner with The Data Incubator for their hiring and training needs, including LinkedIn, Genentech, Capital One, Pfizer, and many others. The program is free for admitted Fellows - see the FAQ below for more information. Fellows have the option to participate in the program either in person in New York City, Washington DC, the San Francisco Bay Area, or online.

The Science of Learning program supports potentially transformative basic research to advance the science of learning. The goals of the SL Program are to develop basic theoretical insights and fundamental knowledge about learning principles, processes and constraints. Projects that are integrative and/or interdisciplinary may be especially valuable in moving basic understanding of learning forward but research with a single discipline or methodology is also appropriate if it addresses basic scientific questions in learning.   The possibility of developing connections between proposed research and specific scientific, technological, educational, and workforce challenges will be considered as valuable broader impacts, but are not necessarily central to the intellectual merit of proposed research. The program will support  research addressing learning in a wide range of domains at one or more levels of analysis including: molecular/cellular mechanisms; brain systems; cognitive affective, and behavioral processes; and social/cultural influences. The program supports a variety of methods including: experiments, field studies, surveys, secondary-data analyses, and modeling.

The Science of Learning program supports potentially transformative basic research to advance the science of learning. The goals of the SL Program are to develop basic theoretical insights and fundamental knowledge about learning principles, processes and constraints. Projects that are integrative and/or interdisciplinary may be especially valuable in moving basic understanding of learning forward but research with a single discipline or methodology is also appropriate if it addresses basic scientific questions in learning.   The possibility of developing connections between proposed research and specific scientific, technological, educational, and workforce challenges will be considered as valuable broader impacts, but are not necessarily central to the intellectual merit of proposed research. The program will support  research addressing learning in a wide range of domains at one or more levels of analysis including: molecular/cellular mechanisms; brain systems; cognitive affective, and behavioral processes; and social/cultural influences. The program supports a variety of methods including: experiments, field studies, surveys, secondary-data analyses, and modeling.

The HFC program seeks proposals for research to develop and test hybrid geopolitical forecasting systems. These systems will integrate human and machine forecasting components to create maximally accurate, flexible, and scalable forecasting capabilities. Human-generated forecasts may be subject to cognitive biases and/or scalability limits. Machine-generated (i.e., statistical, computational) forecasting approaches may be more scalable and data-driven, but are often ill-suited to render forecasts for idiosyncratic or newly emerging geopolitical issues. Hybrid approaches hold promise for combining the strengths of these two approaches while mitigating their individual weaknesses. Performers will develop systems that will integrate human and machine forecasting contributions in novel ways. These systems will compete in a multi-year competition to identify approaches that may enable the Intelligence Community (IC) to radically improve the accuracy and timeliness of geopolitical forecasts.

The HFC program seeks proposals for research to develop and test hybrid geopolitical forecasting systems. These systems will integrate human and machine forecasting components to create maximally accurate, flexible, and scalable forecasting capabilities. Human-generated forecasts may be subject to cognitive biases and/or scalability limits. Machine-generated (i.e., statistical, computational) forecasting approaches may be more scalable and data-driven, but are often ill-suited to render forecasts for idiosyncratic or newly emerging geopolitical issues. Hybrid approaches hold promise for combining the strengths of these two approaches while mitigating their individual weaknesses. Performers will develop systems that will integrate human and machine forecasting contributions in novel ways. These systems will compete in a multi-year competition to identify approaches that may enable the Intelligence Community (IC) to radically improve the accuracy and timeliness of geopolitical forecasts.

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global initiative dedicated to protecting humankind from the most serious bacterial threats to human health by accelerating antimicrobial therapeutics and diagnostics towards clinical development.

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global initiative dedicated to protecting humankind from the most serious bacterial threats to human health by accelerating antimicrobial therapeutics and diagnostics towards clinical development.

The NIGMS Postdoctoral Research Associate (PRAT) Programs overarching goal is to provide high quality postdoctoral research training in the basic biomedical sciences, in NIH intramural research laboratories, to a diverse group of postdoctoral fellows to prepare them for leadership positions in biomedical careers. The research projects proposed should focus on NIGMS mission-related areas of basic biomedical science. These include cell biology, biophysics, genetics, developmental biology, pharmacology, physiology, biological chemistry, computational biology, technology development and bioinformatics. Studies employing model organisms are encouraged

This initiative will support research projects that implement and test comprehensive service approaches to engage and retain youth and young adults (age 12 - 25 years) from health disparity populations in the HIV Treatment Cascade, which includes diagnosis, linkage to care, engagement in care, retention in care, initiation of antiretroviral therapy (ART), and achievement of viral suppression.   

The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohorts to address emerging and high priority research on HIV/AIDS in the context of injection and non-injection substance abuse.  These cohorts provide a strong resource platform for current and future collaborative efforts with other investigators to address emerging questions related to HIV pathogenesis, prevention, and treatment in the context of substance abuse, as well as to foster the creativity and efficiency of investigator-initiated research projects. The diverse research activities among these cohorts include basic immunologic, and virologic studies, as well as studies on HIV prevention and treatment, and the co-morbidities and co-infections associated with HIV and substance abuse.  NIDA has determined that a coordinating center (CC) is needed in order to take advantage of these rich sources of data and bio-specimens and optimize collaborations among both the cohort investigators and other researchers not funded under the cohort program. In addition, the CC is expected to establish a virtual repository, and facilitate the leadership of the cohorts steering committee (SC), consisting of representatives from the NIDA-funded cohorts and NIDA staff. At this time, NIDA is soliciting  cooperative agreement applications for a CC to support the collaborative efforts of the cohorts that are currently funded by NIDA.

The purpose of this Funding Opportunity Announcement (FOA) is to support studies to understand the role of allergen epitope-specific T-cell responses in the pathogenesis and treatment of allergic diseases by utilizing allergen epitope-specific reagents. The FOA will also support novel T-cell epitope identification, characterization and validation of important food allergens and aeroallergens that have not been previously studied.

This Funding Opportunity Announcement (FOA) invites applications for grant funding to conduct Large Health Services Research Demonstration and Dissemination Projects (R18) focused on Combating Antibiotic-Resistant Bacteria (CARB)  

The Agency for Healthcare Research and Quality's (AHRQ) mission is to produce evidence to make health care safer, higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. AHRQ's Center for Quality Improvement and Patient Safety (CQuIPS) is addressing patient safety and medication research by focusing on the safe usage of medications.  This perspective centers on how medications move through the health care system and how this systemic process can be improved so that patients are not harmed, while health care delivery is improved.  CQuIPS encourages the involvement of all members of the health care team, especially patients and families, nurses, pharmacists, technicians (pharmacy and medication administration technicians), health care administrators, risk managers, and physicians across all settings of care, including in the home. This FOA will fund investigative research demonstration projects that examine the effective implementation of processes, policies, and behaviors that support safe use of medication as well as its sustainment and dissemination.

The Agency for Healthcare Research and Quality (AHRQ) is interested in funding a diverse set of projects that develop, test and evaluate various simulation approaches for the purpose of improving the safe delivery of health care. Simulation in health care serves multiple purposes. As a training technique, it exposes individuals and teams to realistic clinical challenges through the use of mannequins, task trainers, virtual reality, standardized patients or other forms, and allows participants to experience in real-time the consequences of their decisions and actions. The principal advantage of simulation is that it provides a safe environment for health care practitioners to acquire valuable experience without putting patients at risk. Simulation also can be used as a test-bed to improve clinical processes and to identify failure modes or other areas of concern in new procedures and technologies that might otherwise be unanticipated and serve as threats to patient safety. Yet another application of simulation focuses on the establishment of valid and reliable measures of clinical performance competency and their potential use for credentialing and certification purposes. The foremost aim of the announcement is to advance patient safety. Keeping this aim in mind, applications that address a variety of simulation techniques, clinical settings, provider groups, priority populations, and patient conditions are welcomed.

The Biotechnology and Biochemical Engineering (BBE) program supports fundamental engineering research that advances the understanding of cellular andbiomolecular processes in engineering biology and eventually leads to the development of enabling technology for advanced manufacturing and/or applications in support of the biopharmaceutical, biotechnology, and bioenergy industries, or with applications in health or the environment. A quantitative treatment of biological and engineering problems of biological processes is considered vital to successful research projects in the BBE program. Fundamental to many research projects in this area is the understanding of how biomolecules, cells and cell populations interact in their environment, and how those molecular level interactions lead to changes in structure, function, phenotype, and/or behavior. The program encourages highly innovative and potentially transformative engineering research leading to novel bioprocessing and manufacturing approaches, and proposals that address emerging research areas and technologies that effectively integrate knowledge and practices from different disciplines while incorporating ongoing research into educational activities. 

The Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and socio-ecological principles and processes that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the cultural, social, behavioral, and economic dimensions of disease transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric diseases of either terrestrial or freshwater systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, modelers, bioinformaticians, genomics researchers, social scientists, economists, epidemiologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.

The goal of this funding opportunity announcement (FOA) is to support pilot testing of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA is not intended to support a randomized controlled trial (RCT) to test the efficacy of the natural product on clinical outcomes.  Rather, the data collected should be used to fill gaps in scientific knowledge and provide the information necessary to develop a competitive full-scale clinical trial.

The goal of this funding opportunity announcement (FOA) is to support pilot testing of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA is not intended to support a randomized controlled trial (RCT) to test the efficacy of the natural product on clinical outcomes.  Rather, the data collected should be used to fill gaps in scientific knowledge and provide the information necessary to develop a competitive full-scale clinical trial.

The goal of this funding opportunity announcement (FOA) is to support pilot testing of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA is not intended to support a randomized controlled trial (RCT) to test the efficacy of the natural product on clinical outcomes.  Rather, the data collected should be used to fill gaps in scientific knowledge and provide the information necessary to develop a competitive full-scale clinical trial.

The goal of this funding opportunity announcement (FOA) is to support pilot testing of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA is not intended to support a randomized controlled trial (RCT) to test the efficacy of the natural product on clinical outcomes.  Rather, the data collected should be used to fill gaps in scientific knowledge and provide the information necessary to develop a competitive full-scale clinical trial.

On September 13, WBI will be hosting its 3rd OEA Collider Event, this time on the topic of Human Performance Enhancement. Please block your calendars from 1:30 till 3:30 and plan to join us to learn more about the opportunities within this massive market space. For the purposes of this project, we're defining Human Performance Enhancement like this: As the world becomes more complex, the demands on human performance continue to increase. Athletic endeavors, military requirements, continuing independence into one's later years are all examples of market-driven needs for human performance enhancement. Strength, speed, endurance, vigilance, multi-tasking, mental-acuity, and recovery are all enhancement opportunities of interest. Formal evaluation of blue papers will begin on approximately 17 October 2016. Wright Brothers Institute continues to work diligently on our pilot project to refine a commercialization process for regional innovators. In March we had an OEA Collider event focused on the Precision Agriculture market which has resulted in 8 Blue Paper submissions and 2 on-going projects to commercialize several of the concepts explained in those blue papers. We're making significant progress toward providing real market solutions with a combination of several innovative technologies!

On September 13, WBI will be hosting its 3rd OEA Collider Event, this time on the topic of Human Performance Enhancement. Please block your calendars from 1:30 till 3:30 and plan to join us to learn more about the opportunities within this massive market space. For the purposes of this project, we're defining Human Performance Enhancement like this: As the world becomes more complex, the demands on human performance continue to increase. Athletic endeavors, military requirements, continuing independence into one's later years are all examples of market-driven needs for human performance enhancement. Strength, speed, endurance, vigilance, multi-tasking, mental-acuity, and recovery are all enhancement opportunities of interest. Formal evaluation of blue papers will begin on approximately 17 October 2016. Wright Brothers Institute continues to work diligently on our pilot project to refine a commercialization process for regional innovators. In March we had an OEA Collider event focused on the Precision Agriculture market which has resulted in 8 Blue Paper submissions and 2 on-going projects to commercialize several of the concepts explained in those blue papers. We're making significant progress toward providing real market solutions with a combination of several innovative technologies!

The goal of theBiomedical Engineering(BME)program is to provide research opportunities to develop novel ideas into discovery-level and transformative projects that integrate engineering and life sciences in solving biomedical problems that serve humanity in the long-term. BME projects must be at the interface of engineering and life sciences, and advance both engineering and life sciences. The projects should focus on high impact transformative methods and technologies. Projects should include methods, models and enabling tools of understanding and controlling living systems; fundamental improvements in deriving information from cells, tissues, organs, and organ systems; new approaches to the design of structures and materials for eventual medical use in the long-term; and novel methods for reducing health care costs through new technologies. The long-term impact of the projects can be related to fundamental understanding of cell and tissue function, effective disease diagnosis and/or treatment, improved health care delivery, or product development.

The goal of theBiomedical Engineering(BME)program is to provide research opportunities to develop novel ideas into discovery-level and transformative projects that integrate engineering and life sciences in solving biomedical problems that serve humanity in the long-term. BME projects must be at the interface of engineering and life sciences, and advance both engineering and life sciences. The projects should focus on high impact transformative methods and technologies. Projects should include methods, models and enabling tools of understanding and controlling living systems; fundamental improvements in deriving information from cells, tissues, organs, and organ systems; new approaches to the design of structures and materials for eventual medical use in the long-term; and novel methods for reducing health care costs through new technologies. The long-term impact of the projects can be related to fundamental understanding of cell and tissue function, effective disease diagnosis and/or treatment, improved health care delivery, or product development.

This Funding Opportunity Announcement (FOA) solicits Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) to develop novel technologies to expand the capability for molecular analyses of banked frozen or formalin-fixed, paraffin-embedded tissues. There is a need for improved tissue preservation methods that maintain histologic features while preserving high quality DNA, RNA, protein and small molecules in archived tissue from rodent and human studies. In addition, novel approaches are needed to preserve DNA, RNA, and small molecules during collection and storage of biological samples.

This Funding Opportunity Announcement (FOA) solicits Small Business Innovative Research (SBIR) grant applications from small business concerns (SBCs) to develop novel technologies to expand the capability for molecular analyses of banked frozen or formalin-fixed, paraffin-embedded tissues. There is a need for improved tissue preservation methods that maintain histologic features while preserving high quality DNA, RNA, protein and small molecules in archived tissue from rodent and human studies. In addition, novel approaches are needed to preserve DNA, RNA, and small molecules during collection and storage of biological samples.